Halaven grows for Eisai but R&D costs hit group profits
This article was originally published in Scrip
Executive Summary
Global sales of Eisai's novel cancer drug Halaven (eribulin) may have risen by 27% in the fiscal first quarter ended 30 June, but at a modest JPY7.0bn ($71 million), the product still has a long way to go to reach its intended blockbuster status.